Jamjoom Pharmaceuticals Factory Company (4015.SR) — Cash flow
Operating, investing, and financing cash flow for Jamjoom Pharmaceuticals Factory Company — annual and quarterly.
| Metric (SAR Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 383↑21.2% | 316↑69.5% | 186↓0.9% | 188↓18.8% | 232 | |
| Depreciation & Amortization | 37↑40.5% | 27↑7.7% | 25↑1.5% | 24↓42.3% | 42 | |
| Deferred Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -165↓234.2% | -49↓50.6% | -33↓223.8% | 26↑233.0% | -20 | |
| Accounts Receivable | -124↓786.6% | 18↑47.9% | 12↓73.9% | 47↑489.9% | 8 | |
| Inventory | -55↑51.6% | -114↓1422.5% | -8↑55.0% | -17↑65.8% | -49 | |
| Accounts Payable | 21↓53.0% | 45↑335.8% | -19↓426.0% | -4↓116.9% | 21 | |
| Other Working Capital | -7↓358.1% | 3↑113.7% | -19↓36.8% | -14↓5761.3% | -0.23 | |
| Other Non-Cash Items | 8↑176.4% | 3↓94.3% | 51↑599.7% | -10↓229.8% | 8 | |
| Net Cash from Operating Activities | 263↓11.1% | 296↑29.2% | 229↑0.2% | 229↓12.7% | 262 | |
| Operating Cash Flow | 263↓11.1% | 296↑29.2% | 229↑0.2% | 229↓12.7% | 262 | |
| Investing Activities | ||||||
| Investment in Property, Plant & Equipment | -57↓24.5% | -46↑47.8% | -88↑30.9% | -127↑22.5% | -164 | |
| Capital Expenditure | -57↓24.5% | -46↑47.8% | -88↑30.9% | -127↑22.5% | -164 | |
| Acquisitions | 0.34↑101.1% | -32↓21479.1% | 0.15↑6.8% | 0.14↓3.0% | 0.14 | |
| Purchases of Investments | 0.00↑100.0% | -32↑4.4% | -33↓73.9% | -19 | 0.00 | |
| Sales & Maturities of Investments | 0.00 | 0.00↓100.0% | 33↑74.4% | 19 | 0.00 | |
| Other Investing Activities | -6↓117.6% | 32↓4.2% | 33↑301.6% | -16↓9.5% | -15 | |
| Net Cash from Investing Activities | -62↑19.6% | -77↓42.1% | -54↑62.0% | -143↑19.7% | -178 | |
| Financing Activities | ||||||
| Net Debt Issuance | -0.31 | 0.00 | 0.00↑100.0% | -95↓252.8% | 62 | |
| Long-Term Net Debt Issuance | -0.31 | 0.00 | 0.00↑100.0% | -95 | 0.00 | |
| Short-Term Net Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 62 | |
| Net Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Buybacks | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | -217↓210.0% | -70↑53.0% | -149↓31.3% | -113↓25.0% | -91 | |
| Common Dividends Paid | -217↓210.0% | -70↑53.0% | -149↓31.3% | -113↓25.0% | -91 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | 0.00↑100.0% | -0.35↓0.0% | -0.35 | 0.00 | 0.00 | |
| Net Cash from Financing Activities | -217↓208.9% | -70↑52.8% | -149↑28.5% | -208↓631.9% | -28 | |
| Cash Reconciliation | ||||||
| Effect of Foreign Exchange | -6↓23.3% | -5↓281.5% | 3↑717.6% | -0.46 | 0.00 | |
| Net Change in Cash | -23↓115.8% | 143↑401.2% | 29↑123.2% | -123↓323.6% | 55 | |
| Cash at Beginning of Period | 284↑101.4% | 141↑25.4% | 113↓52.2% | 236↑30.4% | 181 | |
| Cash at End of Period | 262↓8.0% | 284↑101.4% | 141↑25.4% | 113↓52.2% | 236 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 206↓17.6% | 250↑76.8% | 142↑38.9% | 102↑3.6% | 98 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.